Furthermore, all articles focused on a single cancer/tumour type (CRC, GC, HCC), were published between 2009 and 2025, and reported CDH17 genetic modification or antibody inhibition in in vitro models. This evidence concerns the gene CDH17 and hepatocellular carcinoma.